These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 25147167)

  • 1. Pomalidomide for the management of refractory multiple myeloma.
    Summers BB; Cole SW; Olin JL
    Am J Health Syst Pharm; 2014 Sep; 71(17):1443-8. PubMed ID: 25147167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
    Roziaková L; Mistrík M; Bátorová A
    Klin Onkol; 2014; 27(5):318-25. PubMed ID: 25312708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
    Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
    Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.
    Richardson PG; Mark TM; Lacy MQ
    Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S36-44. PubMed ID: 23786844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetics and Exposure Response Analysis of Pomalidomide in Subjects With Relapsed or Refractory Multiple Myeloma From the Novel Combination Treatment of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone.
    Li Y; Kassir N; Wang X; Palmisano M; Zhou S
    J Clin Pharmacol; 2020 Aug; 60(8):1061-1075. PubMed ID: 32168381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of pomalidomide therapy in multiple myeloma: a recent survey.
    Kumar A; Porwal M; Verma A; Mishra AK
    J Chemother; 2014 Dec; 26(6):321-7. PubMed ID: 25004945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pomalidomide for multiple myeloma.
    Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
    Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
    Hanaizi Z; Flores B; Hemmings R; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
    Oncologist; 2015 Mar; 20(3):329-34. PubMed ID: 25673103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pomalidomide for multiple myeloma].
    Dougé A; Lemal R; Chaleteix C
    Bull Cancer; 2017 Sep; 104(9):707-713. PubMed ID: 28583668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pomalidomide in heavily pretreated refractory multiple myeloma: a case report.
    Palmas A; Piras G; Uras A; Asproni R; Murineddu M; Monne M; Stradoni R; Latte G
    Future Oncol; 2017 Feb; 13(5s):7-9. PubMed ID: 28116939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience.
    Charlinski G; Grzasko N; Jurczyszyn A; Janczarski M; Szeremet A; Waszczuk-Gajda A; Bernatowicz P; Swiderska A; Guzicka-Kazimierczak R; Lech-Maranda E; Szczepaniak A; Wichary R; Dmoszynska A
    Eur J Haematol; 2018 Sep; 101(3):354-361. PubMed ID: 29882602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma.
    Dimopoulos MA; Leleu X; Palumbo A; Moreau P; Delforge M; Cavo M; Ludwig H; Morgan GJ; Davies FE; Sonneveld P; Schey SA; Zweegman S; Hansson M; Weisel K; Mateos MV; Facon T; Miguel JF
    Leukemia; 2014 Aug; 28(8):1573-85. PubMed ID: 24496300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pomalidomide.
    Engelhardt M; Ajayi S; Reinhardt H; Müller SJ; Dold SM; Wäsch R
    Recent Results Cancer Res; 2018; 212():169-185. PubMed ID: 30069630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma.
    Conticello C; Parisi M; Romano A; Calafiore V; Ancora F; La Fauci A; Consoli ML; Di Raimondo F
    Future Oncol; 2017 Feb; 13(5s):3-6. PubMed ID: 28116941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pomalidomide for patients with multiple myeloma.
    Gras J
    Drugs Today (Barc); 2013 Sep; 49(9):555-62. PubMed ID: 24086951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pomalidomide in the treatment of relapsed multiple myeloma.
    Forsberg PA; Mark TM
    Future Oncol; 2013 Jul; 9(7):939-48. PubMed ID: 23837756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma.
    Gay F; Mina R; Troia R; Bringhen S
    Expert Opin Drug Metab Toxicol; 2013 Nov; 9(11):1517-27. PubMed ID: 23961770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma.
    Hoy SM
    Drugs; 2017 Nov; 77(17):1897-1908. PubMed ID: 29110190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pomalidomide. A last-line treatment option for multiple myeloma.
    Prescrire Int; 2014 Nov; 23(154):257-9. PubMed ID: 25954788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
    Lacy MQ; Tefferi A
    Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.